Stock AMOY DIAGNOSTICS CO LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Amoy Diagnostics Co Ltd Stock Shenzhen S.E.

Equities

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E.
Other stock markets
- CNY - Intraday chart for Amoy Diagnostics Co Ltd
Apr. 15 Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 01 Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024. CI

Financials

Sales 2024 * 1.28B 177M Sales 2025 * 1.56B 216M Capitalization 8.6B 1.19B
Net income 2024 * 316M 43.65M Net income 2025 * 383M 52.9M EV / Sales 2024 * 6.13 x
Net cash position 2024 * 722M 99.78M Net cash position 2025 * 1.09B 151M EV / Sales 2025 * 4.8 x
P/E ratio 2024 *
27.4 x
P/E ratio 2025 *
22.7 x
Employees -
Yield 2024 *
0.88%
Yield 2025 *
1.07%
Free-Float 63.15%
More Fundamentals * Assessed data

Latest news about Amoy Diagnostics Co Ltd

Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024. CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China MT
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023 CI
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022. CI
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million. CI
More news

Press releases Amoy Diagnostics Co Ltd

AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC AQ
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan AQ
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel AQ
More press releases

News in other languages on Amoy Diagnostics Co Ltd

AmoyDx conclut un accord-cadre de collaboration avec AstraZeneca pour plusieurs programmes de diagnostics compagnons en Chine, dans l'UE et au Japon
AmoyDx schließt Rahmenkooperationsvereinbarung mit AstraZeneca für mehrere Programme zur begleitenden Diagnostik in China, der EU und Japan ab
More news

Managers and Directors - Amoy Diagnostics Co Ltd

Managers TitleAgeSince
Jie Min Luo CEO
 Chief Executive Officer 41 11-12-31
Li Mou Zheng FOU
 Founder 71 08-02-20
Ying Chen DFI
 Director of Finance/CFO 54 15-03-31
Members of the board TitleAgeSince
Li Mou Zheng FOU
 Founder 71 08-02-20
Fei Luo BRD
 Director/Board Member 46 09-07-31
Xin Huang BRD
 Director/Board Member 76 15-06-17
More insiders

Company Profile

Amoy Diagnostics Co., Ltd. is a China-based company principally engaged in the research and development, manufacturing and sales of molecular diagnostic products for tumor precision medical industry. The Company is also engaged in the provision of relevant testing services. Its products are mainly used to detect the status of tumor-related genes and the provision of scientific basis for tumor-targeted drug selection and individualized treatment programs. The Company mainly distributes its products in the domestic market.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-04-22 - Q1 2024 Earnings Release
More about the company

Sector Diagnostic & Testing Substances

1st Jan change Capi.
BIOMÉRIEUX Stock bioMérieux
-1.14% 12.47B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-17.62% 6.99B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-2.96% 5.1B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+0.53% 4.27B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-6.68% 4.27B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-48.27% 3.45B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+7.09% 2.61B
VITROLIFE AB Stock Vitrolife AB
-14.69% 2.08B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
-3.40% 1.67B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 300685 Stock
  4. Stock